TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychi
Achieves positive Adjusted EBITDA two quarters earlier than expected driven by record high net revenue for the Company of $31.8 million and a top 3 national market share position among Canadian LPs. HIGHLIGHTS Achieved gross revenue of $43.9 million,
RP-3500 shows robust activity in ovarian cancer demonstrating 75% CBR, with 25% ORR and mPFS of 35 weeks Updated monotherapy results show 43% CBR in solid tumors across genotypes, and potential best-in-class safety and tolerability Encouraging data in
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO--(BUSINESS WIRE)--$HMPS #berzerker--Hempsana Holdings Ltd. (the
MONTREAL--(BUSINESS WIRE)--#CB1--Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer, will be presenting at the B
Triumvira to initiate enrollment of second cohort in ongoing Phase 1/2 trial of TAC01-HER2 following data safety monitoring committee’s successful review of safety data from first cohort AUSTIN, Texas, & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira Im
Combination of MVP-S/CPA and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy The combination treatment was well-toler
Record Year of Progress for OxC-betaTM Adoption Worldwide Supply agreement with AB Vista in United States, Brazil and Thailand compliments existing partnerships in Asia and Mexico Continued positive animal trial results leading to orders, new custome
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL #AACR22--AbCellera (Nasdaq: ABCL), a technology company focused on next-generation antibody discovery, today announced the release of data on its new T cell engager platform at the American Association f
Comprehensive Phase 1 monotherapy data from the phase 1/2 TRESR trial will be presented at AACR on Monday, April 11, 2022 at 3:05 p.m. CT Company to host conference call on Monday, April 11, 2022 at 6:30 p.m. ET CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WI
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.